Opko Health Inc (OPK)

[WiseFool]

Update: Laidlaw & Co ‘OPK initiated with “buy”, target $22’

Laidlaw & Co
Aug 12, 2015

Analysts at Laidlaw initiate coverage of Opko Health Inc (OPK) with a “buy” rating. The target price is $22.

Laidlaw notes, “The recent Bio-Reference Laboratories acquisition brings additional revenue plus a large sales force to support OPKs 4Kscore test sales. Coupled with three drugs in OPK’s pipeline that potentially could be approved and enter the market over the next 24 months; the company is in a transformative stage in our opinion. We estimate OPK could become cash positive starting 2016 with continued margin improvements going forward as product mix improves.”